Molecular structure of Etofibrate, CAS Number: 31637-97-5
Etofibrate (CAS 31637-97-5)
See product citations (1)
Alternate Names:
Lipo-Merz
Application:
Etofibrate is a combination of clofibrate and niacin, used to treat hyperlipidaemias
CAS Number:
31637-97-5
Purity:
≥98%
Molecular Weight:
363.79
Molecular Formula:
C18H18ClNO5
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Etofibrate is a combination of niacin and clofibrate (sc-200721) that acts as a hypolipidemic agent. It decreases plasma cholesterol and triglyceride concentrations and increases bile cholesterol content. It also decreases thromboxane formation, platelet aggregation, and plasma viscosity and inhibits neointima formation. Etofibrate has anti-inflammatory, anti-cancer, anti-oxidant, anti-microbial, anti-viral, and anti-fungal properties.
Etofibrate (CAS 31637-97-5) References
- High performance liquid chromatographic determination of etofibrate and its hydrolysis products. | el-Gindy, A., et al. 2007. J Pharm Biomed Anal. 43: 196-203. PMID: 16901673
- Comparative study on the in vivo and in vitro antilipolytic effects of etofibrate, nicotinic acid and clofibrate in the rat. | Bocos, C. and Herrera, E. 1996. Environ Toxicol Pharmacol. 2: 351-7. PMID: 21781742
- The effect of Etofibrate (Lipo-Merz) on 'in vitro' cellular immune response and on lipid parameters of men with myocardial infarction and with arteriosclerosis obliterans. | Horváth, M., et al. 1990. Allergol Immunopathol (Madr). 18: 95-9. PMID: 2371944
- [Effectiveness of etofibrate in arteriosclerosis obliterans. Pilot study in hyperlipidemic patients with arteriosclerosis obliterans]. | Dembińska-Kieć, A., et al. 1989. Fortschr Med. 107: 450-2. PMID: 2767596
- Studies with etofibrate in the rat. Part I: Effects on glycerol, free fatty acid and triacylglycerol metabolism. | Herrera, E., et al. 1988. Biochim Biophys Acta. 963: 42-52. PMID: 3179329
- Bioavailability studies of etofibrate in rhesus monkeys. | Waller, AR., et al. 1985. Arzneimittelforschung. 35: 489-92. PMID: 4039571
- Long-term treatment of hyperlipoproteinemia with etofibrate: clinical observations. | Kaffarnik, H., et al. 1980. Artery. 8: 537-46. PMID: 6114725
- The effect of etofibrate retard, bezafibrate and procetofen. | Luley, C., et al. 1980. Artery. 8: 128-33. PMID: 7458677
- Etofibrate therapy and effect of added low-dose cholestyramine in patients with combined hyperlipidaemia. | Krüger, B. 1994. Int J Clin Pharmacol Res. 14: 177-83. PMID: 7672874
- Effect of etofibrate on bile production in the normolipidemic rat. | Bocos, C., et al. 1995. Gen Pharmacol. 26: 537-42. PMID: 7789727
- [Regression of hard exudates in diabetic background retinopathy in therapy with etofibrate antilipemic agent]. | Freyberger, H., et al. 1994. Med Klin (Munich). 89: 594-7, 633. PMID: 7815987
- Etofibrate increases binding of low and high density lipoprotein to human platelets of patients with type II hyperlipoproteinemia. | Virgolini, I., et al. 1993. Atherosclerosis. 102: 217-26. PMID: 8251008
- Studies with etofibrate in the rat. Part II: A comparison of the effects of prolonged and acute administration on plasma lipids, liver enzymes and adipose tissue lipolysis. | Bocos, C., et al. 1993. Biochim Biophys Acta. 1168: 340-7. PMID: 8323974
- Etofibrate suppresses neointima formation of the ballooned common carotid artery of rats. | Kinscherf, R., et al. 1995. Naunyn Schmiedebergs Arch Pharmacol. 352: 424-8. PMID: 8532071
- Confirmation of efficacy of etofibrate against peripheral atherosclerosis in non-human primates which model human lesion types I-VII. | Fincham, JE., et al. 1996. Arzneimittelforschung. 46: 519-25. PMID: 8737639
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Etofibrate, 100 mg | sc-358229 | 100 mg | $252.00 | |||
Etofibrate, 1 g | sc-358229A | 1 g | $1873.00 |